1 Introduction Allogeneic hematopoietic cell transplantation (alloHCT) cures high-risk hematologic disease, but posttransplant outcomes remain highly variable and nonrelapse mortality (NRM) continues to limit benefit, even among patients with similar disease characteristics [1].
Ivan Pasic
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ivan
Contact Ivan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack